Ceftaroline

General

• Type:
• Dosage Forms:
• Common Trade Names: Teflaro

Adult Dosing

• Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days
• Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days

Special Populations

• Pregnancy Rating:
• Lactation:
• Renal Dosing
  • Adult
    • CrCl > 50 mL/minute: No dosage adjustment necessary
    • CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours
    • CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours
    • CrCl < 15 mL/minute: 200 mg every 12 hours
    • ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
  • Pediatric
    • ≥ 2 months to < 18 years of age
      • CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
      • CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
• Hepatic Dosing
  • Adult
  • Pediatric

Contraindications

• Allergy to class/drug

Pharmacology

• Half-life:
• Metabolism:
• Excretion:
• Mechanism of Action:

Antibiotic Sensitivities

Group	Organism	Sensitivity
Gram Positive	Strep. Group A, B, C, G	S
	Strep. Pneumoniae	S
	Viridans strep	S
	Strep. anginosus gp	X1
	Enterococcus faecalis	S
	Enterococcus faecium	X1
	MSSA	S
	MRSA	S
	CA-MRSA	S
	Staph. Epidermidis	S
	C. jeikeium	X1
	L. monocytogenes	X1
Gram Negatives	N. gonorrhoeae	I
	N. meningitidis	S
	Moraxella catarrhalis	S
	H. influenzae	S
	E. coli	S
	Klebsiella sp	S
	E. coli/Klebsiella ESBL+	R
	E coli/Klebsiella KPC+	R
	Enterobacter sp, AmpC neg	S
	Enterobacter sp, AmpC pos	R
	Serratia sp	S
	Serratia marcescens	X1
	Salmonella sp	S
	Shigella sp	S
	Proteus mirabilis	S
	Proteus vulgaris	S
	Providencia sp.	S
	Morganella sp.	S
	Citrobacter freundii	X1
	Citrobacter diversus	S
	Citrobacter sp.	S
	Aeromonas sp	S
	Acinetobacter sp.	X1
	Pseudomonas aeruginosa	R
	Burkholderia cepacia	R
	Stenotrophomonas maltophilia	R
	Yersinia enterocolitica	X1
	Francisella tularensis	X1
	Brucella sp.	X1
	Legionella sp.	R
	Pasteurella multocida	X1
	Haemophilus ducreyi	X1
	Vibrio vulnificus	X1
Misc	Chlamydophila sp	X1
	Mycoplasm pneumoniae	X1
	Rickettsia sp	X1
	Mycobacterium avium	X1
Anaerobes	Actinomyces	X1
	Bacteroides fragilis	R
	Prevotella melaninogenica	X1
	Clostridium difficile	X1
	Clostridium (not difficile)	X1
	Fusobacterium necrophorum	X1
	Peptostreptococcus sp.	X1

Key

• S susceptible/sensitive (usually)
• I intermediate (variably susceptible/resistant)
• R resistant (or not effective clinically)
• S+ synergistic with cell wall antibiotics
• U sensitive for UTI only (non systemic infection)
• X1 no data
• X2 active in vitro, but not used clinically
• X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
• X4 active in vitro, but not clinically effective for strep pneumonia

References

Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.